Paul J. Elson

Paul J. Elson's AcademicInfluence.com Rankings

Paul J. Elson

Philosophy

#9919

World Rank

#13548

Historical Rank

Ontology

#135

World Rank

#149

Historical Rank

Logic

#6871

World Rank

#8428

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Paul J. Elson's Degrees

PhD Biomedical Sciences University of California, San Francisco
Doctorate Medicine Stanford University

Why Is Paul J. Elson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Paul J. Elson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients (2009) (832)
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. (1992) (710)
A prospective, randomized trial comparing laparoscopic versus conventional techniques in colorectal cancer surgery: a preliminary report. (1998) (668)
Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. (1998) (653)
Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. (2005) (528)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients (2008) (479)
Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. (2001) (344)
Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. (1988) (340)
Prospective, randomized trial comparing laparoscopicvs. conventional surgery for refractory ileocolic crohn's disease (2001) (338)
Clinical features of hypersensitivity reactions to carboplatin. (1999) (335)
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. (2008) (313)
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms (2014) (270)
TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patients (2011) (261)
Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy (2007) (225)
Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. (1995) (218)
A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. (2015) (215)
Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. (2011) (198)
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme (2010) (194)
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. (2009) (193)
Importance of continued testicular suppression in hormone-refractory prostate cancer. (1993) (192)
Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. (1997) (189)
F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. (2003) (184)
The role of laser interstitial thermal therapy in enhancing progression-free survival of difficult-to-access high-grade gliomas: a multicenter study (2014) (179)
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. (2016) (176)
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. (2009) (175)
Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group (2011) (170)
Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. (2007) (164)
Time to initial cancer treatment in the United States and association with survival over time: An observational study (2019) (159)
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. (2008) (159)
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. (2008) (145)
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. (2008) (144)
Prospective, Randomized Trial Comparing Laparoscopic vs. Conventional Surgery for Refractory Ileocolic Crohn’s Disease (2001) (142)
Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. (2003) (129)
Sunitinib rechallenge in metastatic renal cell carcinoma patients (2010) (128)
Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib (2012) (126)
New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. (2009) (116)
Renal Tubulocystic Carcinoma Is Closely Related to Papillary Renal Cell Carcinoma: Implications for Pathologic Classification (2009) (116)
The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. (2007) (114)
A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. (2014) (113)
Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. (2011) (105)
Cervical Cancer Screening by Simple Visual Inspection After Acetic Acid (2001) (105)
Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. (2000) (105)
Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis (2012) (102)
Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. (1999) (98)
Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia (2011) (97)
Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. (1994) (95)
Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma (2005) (95)
HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization (2011) (93)
A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors (2009) (87)
Therapy and outcome of small cell carcinoma of the kidney (2003) (87)
The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. (1993) (85)
Low-Dose Methotrexate Enhances Aminolevulinate-Based Photodynamic Therapy in Skin Carcinoma Cells In vitro and In vivo (2009) (84)
Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. (2011) (84)
Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. (2001) (84)
Prospective Clinical Study of Precision Oncology in Solid Tumors. (2015) (81)
The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. (2012) (81)
Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. (1998) (81)
Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. (2005) (80)
Phase 1 trial of Anvirzel™ in patients with refractory solid tumors (2006) (80)
Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. (1991) (80)
A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced‐dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients (2002) (78)
Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract. (1985) (78)
Participation of community hospitals in clinical trials: analysis of five years of experience in the Eastern Cooperative Oncology Group. (1982) (77)
A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab (2008) (77)
Unfolding the pathophysiological role of bioactive lysophospholipids. (2003) (77)
A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. (2015) (75)
Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. (2004) (74)
Impact of Chromosome 1p Status in Response of Oligodendroglioma to Temozolomide: Preliminary Results (2003) (74)
Multidisciplinary management of colorectal brain metastases (2008) (73)
Prognostic Factors in Patients with Advanced Renal Cell Carcinoma (2004) (73)
Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm. (2017) (72)
Long-term outcomes of Gamma Knife radiosurgery in patients with vestibular schwannomas. (2011) (71)
Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases. (2001) (70)
Sarcomatoid Urothelial Carcinoma of the Bladder: Analysis of 28 Cases With Emphasis on Clinicopathologic Features and Markers of Epithelial-to-Mesenchymal Transition. (2016) (70)
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab (2010) (67)
A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors (2005) (64)
Do older adults presenting with memory complaints wish to be told if later diagnosed with Alzheimer's disease? (2006) (61)
Association of percentage of tumour burden removed with debulking nephrectomy and progression‐free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy (2010) (60)
Surgical outcomes of trigeminal neuralgia in patients with multiple sclerosis. (2013) (57)
Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. (2011) (56)
Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. (2010) (55)
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma (2006) (54)
Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. (2006) (54)
Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma (2002) (51)
Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival. (2005) (51)
G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer (2012) (51)
Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature (2011) (50)
Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma (2013) (50)
Safety and Feasibility of Using Sorafenib in Recurrent Hepatocellular Carcinoma after Orthotopic Liver Transplantation (2010) (50)
Prevalence of cervical cancer and feasibility of screening in rural China: a pilot study for the Shanxi Province Cervical Cancer Screening Study. (1999) (50)
The sensitivity of initial transurethral resection or biopsy of bladder tumor(s) for detecting bladder cancer variants on radical cystectomy. (2013) (49)
MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. (2006) (49)
Inflation of Sensitivity of Cervical Cancer Screening Tests Secondary to Correlated Error in Colposcopy (2006) (48)
Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients (2018) (47)
Reducing Time to Antibiotic Administration for Febrile Neutropenia in the Emergency Department. (2015) (46)
Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. (2009) (46)
Functional Outcomes Following Chemoradiotherapy for Head and Neck Cancer (2003) (44)
Interferon-alpha and survival in renal cell cancer. (1995) (43)
Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma (2005) (43)
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. (2010) (42)
Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials. (2012) (42)
Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target (2018) (41)
An eastern cooperative oncology group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma (1994) (41)
Phase II Trial of Liposomal Doxorubicin (Doxil®) in Advanced Soft Tissue Sarcomas (2000) (40)
Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response. (1997) (39)
CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes. (2010) (39)
Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated with Mortality in Patients with Prostate Cancer (2013) (39)
Sunitinib‐induced macrocytosis in patients with metastatic renal cell carcinoma (2008) (39)
Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. (2018) (39)
Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma (1988) (38)
Role of Gamma Knife surgery in patients with 5 or more brain metastases. (2012) (37)
The colposcopic impression. Is it influenced by the colposcopist's knowledge of the findings on the referral Papanicolaou smear? (2001) (37)
A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma. (2017) (35)
Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas (2011) (35)
Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens (1982) (34)
Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. (2005) (33)
A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma. (2016) (32)
RANDOMIZED PHASE II EVALUATION OF CARBOPLATIN AND CHIP IN ADVANCED TRANSITIONAL CELL CARCINOMA OF THE UROTHELIUM (1990) (30)
Telomerase activity in Stage II colorectal carcinoma (2002) (30)
Absolute lymphocyte count at day 28 independently predicts event‐free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia (2012) (29)
Transforming Growth Factor-β Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2-Dependent Bladder Cancer Cell Migration and Invasion. (2016) (29)
Prognostic Factors in Metastatic Renal Cell Carcinoma (2000) (29)
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects (2011) (29)
Enhanced IMP3 Expression Activates NF-кB Pathway and Promotes Renal Cell Carcinoma Progression (2015) (28)
Tumor progression in patients receiving adjuvant whole-brain radiotherapy vs localized radiotherapy after surgical resection of brain metastases. (2015) (27)
Primary Screening with Liquid-Based Cytology in an Unscreened Population in Rural China, with an Emphasis on Reprocessing Unsatisfactory Samples (2002) (27)
Spindle Cell Lipomas in Women: A Report of 53 Cases (2017) (27)
Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1–3 newly diagnosed brain metastases (2015) (27)
Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial. (2011) (27)
The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib (2011) (27)
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia (2019) (26)
Histological pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of Stage III patients (2016) (26)
Phase II study of Dovitinib in recurrent glioblastoma (2019) (26)
Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC). (2010) (25)
Role of TMPRSS2-ERG Gene Fusion in Negative Regulation of PSMA Expression (2011) (25)
Comparison of melphalan with cyclophosphamide, methotrexate, and 5‐fluorouracil in patients with ovarian cancer (1984) (25)
Predictive factors for latency period and a prognostic model for survival in patients with therapy‐related acute myeloid leukemia (2014) (25)
VEGF single nucleotide polymorphisms (SNPs) and correlation to sunitinib-induced hypertension (HTN) in metastatic renal cell carcinoma (mRCC) patients (pts). (2009) (25)
Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) -targeted therapy in metastatic renal cell carcinoma (RCC) (2007) (25)
Longitudinal experience with WHO Grade III (anaplastic) meningiomas at a single institution (2017) (25)
Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint (2017) (24)
High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study. (1987) (24)
Decreased serum phosphate levels after high-dose estrogens in metastatic prostate cancer. Possible implications. (1984) (24)
Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery. (2019) (24)
5-Azacytidine (NSC 102816) in refractory germ cell tumors (1993) (24)
Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib (2007) (24)
Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer (2017) (23)
Clinical and immunomodulatory effects of bevacizumab and low‐dose interleukin‐2 in patients with metastatic renal cell carcinoma: results from a phase II trial (2011) (23)
Efficacy of rabbit antithymocyte globulin in severe aplastic anemia (2011) (23)
Predictors of outcome in post-transplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors (2009) (23)
Time to surgery and its impact on survival in patients with endometrial cancer: A National cancer database study. (2019) (22)
Phase II trial of patupilone in patients with brain metastases from breast cancer. (2014) (22)
Clinical outcome of stereotactic radiosurgery for central nervous system metastases from renal cell carcinoma. (2014) (20)
Quantitative Evaluation of Local Control and Wound Healing Following Surgery and Stereotactic Spine Radiosurgery for Spine Tumors. (2016) (20)
Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylated Arginine Deiminase. (2017) (20)
Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma (2017) (19)
Dual VEGF/VEGFR inhibition in advanced solid malignancies (2014) (19)
Sunitinib and bevacizumab in advanced solid tumors: A phase I trial (2008) (19)
Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): Safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy (2008) (18)
Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy (2015) (18)
Gemcitabine and docetaxel in metastatic, castrate‐resistant prostate cancer (2011) (18)
Phase II trial of misonidazole (MISO) and cyclophosphamide (CYC) in metastatic renal cell carcinoma. (1986) (18)
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma (2001) (17)
T regulatory cells (Treg) in patients with metastatic renal cell carcinoma (mRCC) decrease during sunitinib treatment: Correlations with clinical responses and T helper 1/T helper 2 (Th1/Th2) bias. (2006) (17)
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study (2015) (17)
Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS) (2005) (16)
A Single Institution Review of Adjuvant Therapy Outcomes for Resectable Pancreatic Adenocarcinoma: Outcome and Prognostic Indicators (2010) (16)
Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study. (1991) (16)
Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12. (1999) (16)
Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial. (2014) (16)
A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer (2004) (16)
Phase 1 Trial of Subcutaneous IL-6 in Patients With Refractory Cancer: Clinical and Biologic Effects (2000) (15)
A prospective observational study of metastatic renal cell carcinoma (mRCC) prior to initiation of systemic therapy. (2014) (15)
Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma (2018) (15)
Clinical and Immunomodulatory Effects of Celecoxib Plus Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients with COX-2 Tumor Immunostaining (2011) (15)
Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis (2017) (15)
Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma (2014) (15)
Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma (2008) (15)
Clinical activity of ketoconazole and lenalidomide in castrate progressive prostate carcinoma (CPPCA): Preliminary results of a phase II trial (2008) (15)
Clinical and Biological Effects of Neoadjuvant Sargramostim and Thalidomide in Patients with Locally Advanced Prostate Carcinoma (2008) (14)
A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma (2012) (14)
Renal cell carcinoma (RCC) and telomerase activity: relationship to stage. (2003) (13)
Phase II study of PALA and AMSA in advanced renal cell carcinoma. (1983) (13)
Differential Immunologic and MicroRNA Effects of 2 Dosing Regimens of Recombinant Human Granulocyte/Macrophage Colony Stimulating Factor (2012) (12)
Phase I/II trial of subcutaneous interleukin‐2, granulocyte‐macrophage colony‐stimulating factor and interferon‐α in patients with metastatic renal cell carcinoma (2012) (12)
Phase I/II trial of GM-CSF and lenalidomide in patients with hormone refractory prostate cancer (HRPC) (2007) (11)
A Phase I Trial of Weekly Gemcitabine and Subcutaneous Interferon Alpha in Patients with Refractory Renal Cell Carcinoma (2002) (11)
Drug Holiday in Metastatic Renal‐Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors (2018) (11)
Erratum: "Shanxi Province Cervical Cancer Screening Study: A Cross-Sectional Comparative Trial of Multiple Techniques to Detect Cervical Neoplasia," (Gynecologic Oncology (2001) 83:2(439-444) (2002) (11)
Clinical and Radiographic Outcomes From Repeat Whole-brain Radiation Therapy for Brain Metastases in the Age of Stereotactic Radiosurgery (2016) (11)
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. (2008) (11)
Phase Ι trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease (2008) (11)
Sunitinib in patients (pts) with unresectable primary renal cell carcinoma (RCC). (2016) (11)
Phase I trial of thalidomide and Interleukin-2 in patients with metastatic renal cell carcinoma (2006) (10)
Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL) (2011) (10)
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies (2003) (10)
Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings. (1996) (10)
Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancer (2004) (10)
Outcomes of treatment cessation in select metastatic renal cell carcinoma (mRCC) patients. (2014) (9)
Increase in time to initiating cancer therapy and association with worsened survival in curative settings: A U.S. analysis of common solid tumors. (2017) (9)
Chemotherapy for Acute Myelogenous Leukemia in the Elderly With Cytarabine, Mitoxantrone, and Granulocyte-Macrophage Colony-Stimulating Factor (2001) (9)
Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study. (1982) (9)
Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors in solid tumors. (2016) (9)
Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects. (2003) (9)
Lung cancer treatment outcomes in recipients of lung transplant. (2015) (9)
Timed sequential chemotherapy with concomitant Granulocyte Colony-Stimulating Factor for high-risk acute myelogenous leukemia: a single arm clinical trial (2002) (9)
Carboplatin in advanced, refractory germ cell neoplasms: a phase II Eastern Cooperative Oncology Group Study. (1987) (9)
Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment-induced neutropenia. (2003) (9)
Association of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinoma. (2013) (9)
Contrast enhanced CT (CE-CT) changes and nephrometry down-scoring of unresectable primary renal cell carcinoma (RCC) tumors in patients (Pts) treated with neoadjuvant sunitinib. (2011) (8)
Neuropathy and Efficacy Of Weekly Subcutaneous Bortezomib In Myeloma and AL Amyloidosis (2013) (8)
Association of percentage of tumor burden removed with debulking nephrectomy and progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC) patients (Pts) treated with VEGF-targeted therapy. (2009) (8)
Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity. (2007) (8)
Correction: Time to initial cancer treatment in the United States and association with survival over time: An observational study (2019) (8)
Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study. (2006) (8)
Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer (1998) (8)
Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma. (1987) (8)
Potential non-synonymous single nucleotide polymorphisms (nsSNPs) associated with toxicity in metastatic clear cell renal cell carcinoma (MCCRCC) patients (pts) treated with sunitinib (2008) (8)
Undifferentiated endometrial carcinoma: a National Cancer Database analysis of prognostic factors and treatment outcomes (2019) (8)
Time from Diagnosis to Treatment Initiation Predicts Survival in Acute Myeloid Leukemia (AML). (2007) (8)
Modulation of immune cell infiltrate with sunitinib to improve anti-PD1 therapy in preclinical tumor model (2015) (8)
Pre-treatment hematological markers as a predictive biomarker for survival in patients with non-small cell lung cancer treated with nivolumab. (2017) (7)
Phase II trial of dovitinib in recurrent glioblastoma. (2015) (7)
Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology Group. (1990) (7)
Elevated blood &bgr;-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal melanoma (2013) (7)
Sunitinib in BCG-refractory non-muscle-invasive transitional cell carcinoma of the bladder. (2011) (6)
GM-CSF safety and effects in the management of advanced/refractory multiple myeloma patients: a phase I trial (2001) (6)
Treatment of metastatic prostate cancer an analysis of response criteria in patients with measurable soft tissue disease (1984) (6)
Spine Tumors: A Prospective Assessment of Spine Radiosurgery on Pain and Quality of Life (2009) (6)
Acta Cytologica 40 Years Ago (2004) (6)
Clinical factors associated with outcome in metastatic renal cell carcinoma patients treated with VEGF-targeted therapy (2007) (6)
A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia Undergoing Remission Induction Therapy (2016) (6)
Quality of institutional participation in multicenter trials. (1982) (6)
A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC) (2007) (6)
Cancer Therapy : Preclinical Low-Dose Methotrexate Enhances Aminolevulinate-Based Photodynamic Therapy in Skin Carcinoma Cells In vitro and In vivo (2009) (5)
The "real-life" variability of CA-125 in ovarian cancer patients. (2006) (5)
Venous thromboembolism in patients with glioblastoma: Risk factors and prognostic importance. (2015) (5)
A retrospective multicenter study of MSKCC poor-prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib (2008) (5)
Neoadjuvant GM-CSF and thalidomide in men with high-risk prostate carcinoma undergoing radical prostatectomy. (2006) (5)
Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes (2011) (5)
Analysis of Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated in Randomized Clinical Trials (2016) (5)
Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma (2004) (5)
Metastatic renal cell carcinoma (mRCC) patients (pts) with sarcomatoid features treated with VEGF-targeted therapy (2008) (5)
Phase II study of lenalidomide in patients (pts.) with metastatic renal cell carcinoma (MRCC). (2006) (5)
A phase II study of pazopanib (P) in patients (Pts) with localized renal cell carcinoma (RCC) to enable partial nephrectomy (PN). (2014) (4)
Frequency and survival impact of osseous metastases in patients with untreated renal cell carcinoma. (2004) (4)
Use of the fast Fourier transform algorithm in the calculation of the operating characteristics of group sequential clinical trials (1995) (4)
Long term toxicity of tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma (RCC) (2008) (4)
The Degree and Effect Of Weight Loss In Acute Myeloid Leukemia Patients Receiving Induction and Post-Remission Chemotherapy (2013) (4)
Lenalidomide Related Diarrhea Correlates With Survival In Multiple Myeloma (2013) (4)
Role of VEGF and VEGFR2 single nucleotide polymorphisms (SNPs) in predicting treatment-induced hypertension (HTN) and clinical outcome (CO) in metastatic clear cell RCC (mccRCC) patients (pts) treated with sunitinib. (2010) (4)
PD1, PDL1, PDL2 tumor tissue (TT) expression as predictors of response to neoadjuvant chemotherapy (NAC) and outcome in bladder cancer (BC). (2016) (4)
Thyroid hormones and lung cancer: Primary hypothyroidism is prognostically significant for survival in lung cancer (2004) (4)
Comment on: Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma (2008) (4)
Evaluation of carboplatin (NSC 241240) in patients with recurrent or metastatic renal cell carcinoma (1990) (4)
Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/ Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial (2014) (4)
Prognostic factors for survival in patients with metastatic renal cell carcinoma: a study from the Kidney Cancer Association’s International Kidney Cancer Working Group (IKCWG) (2005) (4)
WBC changes as a pharmacodynamic marker of outcome in metastatic renal cell carcinoma (mRCC) patients (Pts) receiving sunitinib (2007) (4)
Decreased Serum Phosphate Levels after High-Dose Estrogens in Metastatic Prostate Cancer. Possible Implications (1984) (4)
Impact of allogeneic hematopoietic stem cell transplant (HSCT) on patients harboring the spliceosome mutation SRSF2. (2013) (4)
Expression of FLT3 and VEGFR1 on myeloid derived suppressor cells (MDSC) in renal cell carcinoma (RCC) patients (Pts) (2008) (3)
Multidisciplinary Management of Colorectal Cancer Brain Metastases: A Retrospective Study (2007) (3)
CCL 2 Expression in Primary Ovarian Carcinoma Is Correlated with Chemotherapy Response and Survival Outcomes (2010) (3)
Correlation between gene expression and prognostic biomarkers in small cell bladder cancer (SCBC). (2018) (3)
Contemporary use of radium-223 (Ra-223) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Feasibility and safety. (2015) (3)
A phase Ib trial of an anti-idiotypic vaccine for Lewis Y (IGN 301) administered subcutaneously in patients with refractory solid tumors (2004) (3)
Informed decision making (IDM) for prostate cancer (PCa) screening in a high-risk population. (2017) (3)
Treatment of Cancer Associated Venous Thrombosis; The Cleveland Clinic Experience (2017) (3)
Predicting venous thromboembolism in hospitalized cancer patients: a risk assessment tool. (2016) (3)
Trimetrexate in advanced renal cell carcinoma (1992) (3)
Predictive Factors for Latency Period and a Prognostic Model for Survival in Patients with Therapy-Related AML. (2012) (3)
Impact of BRAF mutation in patients with brain metastasis from melanoma. (2015) (3)
Molecular profiling of small cell bladder cancer (SCBC) to reveal gene expression determinants of an aggressive phenotype. (2017) (3)
Prognostic Factors for Survival in Metastatic Renal Cell Carcinoma (2008) (3)
Serial measurements of myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint inhibitors (CI). (2017) (3)
A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Bortezomib for Relapsed/Refractory Acute Myeloid Leukemia (2012) (3)
Immune cell changes in the peripheral blood of metastatic renal cell carcinoma (mRCC) patients (pts) treated with sunitinib or temsirolimus (2008) (3)
Efficacy of Rabbit Anti-Thymocyte Globulin (ATG) Compared to Horse ATG In Severe Aplastic Anemia (2010) (3)
Is adjuvant radiation plus chemotherapy for resectable pancreatic adenocarcinoma associated with improved survival? The Cleveland Clinic experience (2008) (3)
Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib. (2014) (3)
Accumulation of MDSC subsets in renal cell carcinoma correlates with grade and progression free survival, and is associated with intratumoral expression of IL-1β, IL-8 and CXCL5 (2014) (3)
Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC Regimen)in advanced malignancies (2010) (3)
A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia. (2020) (3)
Evaluation of Prognostic Factors for Early Mortality After Stereotactic Radiosurgery for Brain Metastases: a Single Institutional Retrospective Review (2018) (2)
Glioblastoma in the elderly: The Cleveland Clinic experience (1992-2010). (2011) (2)
Adjuvant enzalutamide (Enza) for men with non-metastatic high-risk prostate cancer (HRPCa) after radical prostatectomy (RP). (2018) (2)
Impact of vaginal brachytherapy on survival in stage I endometrioid endometrial carcinoma (2020) (2)
Inhibition of the IGF pathway in metastatic castrate resistant prostate cancer (CRPC): Results from a phase II study of OSI-906 (linsitinib). (2013) (2)
Factors associated with tumor recurrence and 5-year postoperative survival in ampullary carcinoma: Cleveland Clinic Experience (2008) (2)
Significance of epidermal mitoses in challenging melanocytic proliferations (2017) (2)
New graded prognostic index for breast cancer patients (pts) with brain metastases (BCBM). (2014) (2)
Development of a Prognostic Scoring System for Secondary Acute Myeloid Leukemia (sAML) Arising from Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders (MPD), or Therapy-Related AML (t-AML). (2008) (2)
Impact of Red Blood Cell and Platelet Transfusions in Acute Myeloid Leukemia (AML) Patients Undergoing Remission Induction Chemotherapy (2015) (2)
Impact of BRAF Mutation on Outcome Following Stereotactic Radiosurgery in Melanoma Brain Metastases (2015) (2)
Survival Outcomes of Leukemias and Myelodysplastic Syndromes Occurring As Second Cancers in the United States: A SEER Registry-Based Population Analysis (2015) (2)
A phase II trial of melphalan or thioguanine in the treatment of patients with advanced renal cell cancer. (1996) (2)
Assessment of blood and tissue myeloid derived suppressor cells (MDSC), clinicopathologic factors, and treatment response in urothelial carcinoma (UC) patients (pts) undergoing surgery. (2017) (2)
Diffuse Large B Cell Lymphoma: Role Of MYC, BCL2, BCL6 Protein Expressions and Translocations (2013) (2)
Short communication: phase I clinical and gene modulatory evaluation of tamoxifen and IFN-alpha2b. (2006) (2)
Aggressive Treatment is Appropriate for Elderly (70 years and older) Patients with Glioblastoma Multiforme: A Retrospective Review of 206 Cases (2008) (2)
A comparison of combination therapies for advanced endometrial cancer (1981) (2)
A validation study of graded prognostic assessment index for lung cancer patients with brain metastases. (2013) (2)
Prognostic value of DLL3 expression and clinicopathologic features in small cell bladder cancer (SCBC). (2017) (2)
Trimetrexate in advanced renal cell carcinoma. An ECOG phase II trial. (1992) (2)
Predictors for Recurrent 30-Day Unplanned Readmissions in Patients with Hematologic Malignancies (2017) (2)
A phase II study of linsitinib (OSI-906) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). (2013) (2)
New Classification Scheme to Predict Survival in Patients with Brain Metastases from Non-small Cell Lung Cancer Treated with Upfront Stereotactic Radiosurgery (2008) (2)
Effect of sulindac sulfone on proliferation, apoptosis, and polyps in a clinical trial in familial adenomatous polyposis (FAP) with rectal polyps* (1998) (2)
An observational study of metastatic renal cell carcinoma patients prior to initiation of initial systemic therapy. (2012) (2)
SHANXI PROVINCE CERVICAL CANCER STUDY A CROSS-SECTIONAL COMPARATIVE TRIAL OF MULTIPLE TECHNIQUES TO DETECT CERVICAL NEOPLASIA (2008) (2)
A consensus prognostic factor model for survival in patients with metastatic renal cell carcinoma: A Kidney Cancer Association's International Kidney Cancer Working Group (IKCWG) study (2007) (2)
Association of the development of bone metastases with the development of brain metastases in patients with non-small cell lung cancer. (2013) (1)
Sunitinib ReversesType-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients (2008) (1)
Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy (2011) (1)
Consequences of Chemotherapy Induced Myelosuppression In Patients with Chronic Lymphocytic Leukemia (CLL) (2010) (1)
Impact of Day 28 Absolute Lymphocyte Count On Outcome of Hematopoietic Cell Transplant (HCT) in CR1 for Adult Patients with Acute Lymphoblastic Leukemia (2012) (1)
Graded prognostic assessment index for renal cell carcinoma with brain metastases. (2013) (1)
BM-20EVALUATION OF RISK FACTORS FOR DEATH WITHIN THREE MONTHS AFTER STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES. (2014) (1)
Original article Phase II trial of GM-CSF thalidomide in patients with androgen- independent metastatic prostate cancer (2005) (1)
Vancomycin-Resistant Enterococcus (VRE) Bacteremia During Acute Myeloid Leukemia (AML) Induction Therapy Is an Independent Predictor of Poor Outcome (2012) (1)
Graded prognostic assessment index for breast cancer patients with brain metastases (BCBM). (2013) (1)
Comparison of Prognostic Factors and Outcomes of Patients with Secondary Acute Myeloid Leukemia (AML) Following Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders (MPD), or Therapy-Related AML (t-AML). (2007) (1)
BM-03REVISED GRADED PROGNOSTIC ASSESSMENT FOR MELANOMA PATIENTS WITH BRAIN METASTASIS (MBM). (2014) (1)
Abstract P6-16-12: Graded prognostic assessment for triple negative breast cancer brain metastases (2015) (1)
BM-02NEW DISEASE SPECIFIC GRADED PROGNOSTIC ASSESSMENT OF BRAIN METASTASIS FROM LUNG, BREAST, MELANOMA AND RENAL MALIGNANCIES (2014) (1)
Unclassified renal cell carcinoma (RCC): Analysis of clinical and pathologic features (2008) (1)
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma (2016) (1)
Abstract 4378: Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma (2012) (1)
Prognostic Impact of Molecular Mutations in AML at First Relapse (2015) (1)
A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML): Final Results (2017) (1)
Adjuvant enzalutamide (Enza) for men with high-risk prostate cancer (HRPCa) after radical prostatectomy (RP). (2016) (1)
Is rituximab sub-optimally dosed in indolent B cell lymphoma? (2015) (1)
LFA-3/CD2 Pathway, Potential Target For Immunosuppressive Therapy In Aplastic Anemia: A Phase I/II Trial Of Alefacept In Patients With Relapsed/Refractory Aplastic Anemia (2013) (1)
The participation of community hospitals in cancer clinical trials: results and impact of the Eastern Cooperative Oncology Group Program. (1983) (1)
Clinical effect of TKI dose-escalation after disease progression in patients with metastatic renal cell carcinoma. (2015) (1)
Evaluation of patient (Pt), treatment, and prognostic factors in urinary tract adenocarcinoma. (2017) (1)
Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma (2010) (1)
An alternative titration schedule of axitinib in metastatic renal cell carcinoma. (2015) (1)
The real-life variability of CA 125 in ovarian cancer patients. (2004) (1)
Doxil (d), vincristine (v), & decadron (d)(dvd) has a strong antiangiogenic activity in newly diagnosed multiple myeloma(mm) patients (pts) (2000) (1)
The effect of routine early palliative care (PC) consultation on aggressiveness of care at the end of life (EOL) in patients with advanced non-small cell lung cancer (NSCLC). (2016) (1)
Medical and Neuro-Oncology (2010) (1)
Risk factor migration and survival: Analysis from international dataset of 3,748 metastatic renal cell carcinoma (mRCC) patients treated on clinical trials. (2011) (1)
Graded prognostic assessment index for melanoma with brain metastases (MBM). (2013) (1)
Validation study of graded prognostic assessment (GPA) of non-small cell lung cancer (NSCLC) patients with brain metastasis (BM). (2014) (1)
Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia (2011) (1)
Graded prognostic assessment (GPA) of HER2 positive breast cancer patients with brain metastases. (2015) (1)
A History of Abnormal Bleeding Correlates with Platelet Dysfunction in Aggregation Studies but Not PFA-100 Analyses (2015) (1)
O1.02NEW GRADED PROGNOSTIC INDEX FOR RENAL CELL CARCINOMA PATIENTS WITH BRAIN METASTASES (RCCBM) (2014) (1)
Effect of pazopanib on myeloid-derived suppressor cells and T-cell function in patients with metastatic renal cell carcinoma. (2013) (1)
Macrocytosis in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKI's) (2007) (1)
Follicular PD-1+ Lymphocytes in the Tumor Microenvironment Are An Independent Prognostic Factor in Follicular Lymphoma. (2009) (1)
A quantitative and comparative evaluation of stereotactic spine radiosurgery local control: proposing a consistent measurement methodology. (2022) (1)
Prophylactic use of Granulocyte-colony stimulating factors (G-CSF) in cancer patients: Adherence to NCCN guidelines. (2016) (1)
Distinct Pattern Of Genomic Changes Associated With Smoking In Patients With Myelodysplastic Syndromes (MDS) (2013) (1)
Characteristics, Mutation Profiles and Outcomes of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease (2017) (0)
Do older adults with early memory loss wish to be told if subsequently diagnosed with Alzheimer’s disease? (2007) (0)
Use of single polymorphism arrays (SNP-A) to modify prognostic scoring systems for myelodysplastic syndromes. (2012) (0)
Duration of Antecedent Complete Blood Cell Count (CBC) Abnormalities Predicts Response and Survival Rates In De Novo and Secondary AML. (2010) (0)
A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed C-Kit Positive Acute Myeloid Leukemia (AML) (2012) (0)
MPTH-04LOMUSTINE AS SALVAGE THERAPY IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (2015) (0)
The association between the treatment-induced hypertension (Htn) and response to neoadjuvant sunitinib in renal cell carcinoma (RCC). (2012) (0)
A translational phase II trial of celecoxib plus interferon-alpha (IFN-α2b) in metastatic renal cell carcinoma (RCC) patients (pts) with 3+ COX-2 tumor immunostaining. (2009) (0)
Prospective Study Of An Emergency Department Febrile Neutropenia Pathway In Patients With Hematologic Malignancies (2013) (0)
Clinical outcome of gamma knife (GK) radiotherapy for central nervous system (CNS) metastases from renal cell carcinoma (RCC). (2011) (0)
Original article Phase II trial of capecitabine and rHu-interferon--2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity (2007) (0)
Adult low-grade gliomas: The Cleveland Clinic experience. (2012) (0)
Who benefits from liver-directed therapy (LDT) for colorectal liver metastases (CRLM)? Development of a prognostic model. (2015) (0)
SURG-20A MULTICENTER SURVIVAL ANALYSIS OF UPFRONT LASER-ABLATION FOR TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2015) (0)
Diastolic but Not Systolic Heart Failure Is Associated with Multiple Abnormalities on Platelet Aggregation Testing (2015) (0)
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma (2016) (0)
Breaking the news to carers that their relative suffers from dementia : an exploratory study. (1995) (0)
Evaluation of response to enzalutamide (E) consecutively after disease progression on abiraterone/prednisone (AP) and potential predictors of response. (2016) (0)
Prognostic factors for outcome in metastatic renal cell carcinoma (2007) (0)
High dose therapy (HDT) and autologous stem cell transplantation (ASCT) in diffuse large B cell lymphoma (DLBL) patients with secondary central nervous system (CNS) involvement (2004) (0)
A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML) (2016) (0)
Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature (2011) (0)
Temsirolimus in VEGF-refractory metastatic renal cell (2011) (0)
Abstract 1810: PTEN association with mTOR pathway activation and outcomes in bladder cancer (2010) (0)
Role of quantitative gene expression using RT-PCR in the prediction of recurrence risk in resected T1 clear cell renal cell carcinoma (ccRCC). (2011) (0)
Comparison of microfilter-based capture to CellSearch in detection of circulating tumor cells (CTCs) in patients with metastatic castration-resistant prostate cancer (mCRPCa). (2014) (0)
Prognostic Factors for Survival in Patients with Recurrent or Metastatic Renal Cell Carcinoma 1 (2006) (0)
Clinical implications of routine testing for epidermal growth factor receptor (EGFR) mutations in patients with nonsquamous non-small cell lung cancer (NSCLC). (2013) (0)
Prognostic Factors for Adult Low Grade Glioma Patients 40 Years of Age and Younger (2015) (0)
Abstract 4712: Targeting the arginine-nitric oxide pathway to arrest development and progression of invasive bladder cancer (2015) (0)
Clinical F eatures o f H ypersensitivity Reactions t o C arboplatin (1999) (0)
A phase Ib trial of an anti-idiotypic vaccine for Lewis Y (IGN 301) administered subcutaneously in patients with refractory solid tumors. (2004) (0)
Graded Prognostic Index for Gastroesophageal Cancer with Brain Metastases. (2016) (0)
The impact of switching systemic treatment after radiosurgery (SBRT) for oligo-progressive, metastatic renal cell carcinoma (mRCC). (2018) (0)
Clinical and Biological Effects of Neoadjuvant Sargramostim and Thalidomide in Patients with LocallyAdvanced Prostate Carcinoma (2008) (0)
Patient/treatment characteristics and prognostic factors in small-cell bladder cancer (SCBC). (2016) (0)
Long-Term Cryopreservation of Autologous Stem Cell Grafts: Impact of Patient Age, Initial Collection, and Stem Cell Mobilization Regimen. (2010) (0)
Transforming Growth Factor- b Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2 e Dependent Bladder Cancer Cell Migration and Invasion (2016) (0)
Value of International Prognostic Score (IPS) in predicting need for bone marrow biopsy (BMB) in Hodgkin's lymphoma (HL). (2009) (0)
Abstract 11: Arginine deprivation therapy using ADI-PEG20 as a novel therapeutic modality in the treatment of bladder cancer. (2013) (0)
New graded prognostic index (GPI) for melanoma patients with brain metastasis (MBM). (2014) (0)
Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML) (2015) (0)
Impact of Radiosurgery Dose for Brain Metastases Less Than or Equal to 2 cm in Size (2016) (0)
Correlation of myeloid derived suppressor cell (MDSC) populations with clinicopathologic features in urothelial carcinoma (UC). (2016) (0)
Survival Outcome of Patients (≥80 Years) With Small Cell Lung Cancer: A Retrospective Study (2014) (0)
Abstract P5-14-07: Impact of time to treatment (TTT) on recurrence free survival in non metastatic invasive breast cancer (2017) (0)
Evaluation of blood and tissue myeloid derived suppressor cells (MDSC), clinicopathologic factors, and pathologic response in urothelial carcinoma (UC). (2016) (0)
Real-world experience with atezolizumab (atezo) in advanced urothelial cancer (UC). (2017) (0)
Circulating Tumor Cells (CTCs) in Advanced Lung Cancer: Prognostic Impact of Quantification and Morphology by 2 Separate Techniques (2014) (0)
Defining quality and value in a prospective study of an emergency department (ED) febrile neutropenia pathway (FNP). (2014) (0)
Predictors of outcome for pemetrexed (Pem) in metastatic NSCLC (mNSCLC). (2013) (0)
Prognostic markers assessment in invasive upper tract urothelial carcinoma (UTUC). (2016) (0)
Comparison of Very Low-Dose Decitabine to Standard-Dose Hypomethylating Agents in Myelodysplastic Syndromes (MDS) (2014) (0)
Results of Stereotactic Radiosurgery for Brain Metastases From Breast Cancer (2007) (0)
Quality of life in patients with pure and mixed anaplastic oligodendroglioma treated with dose-intense temozolomide: A phase II multicenter study. (2010) (0)
EPID-11WHO GRADE 3 GLIOMAS: CLINICAL AND MOLECULAR PROGNOSTIC FACTORS. (2015) (0)
Impact of Myocardial Infarction On Survival in Acute Myeloid Leukemia (2012) (0)
Revised graded prognostic assessment (GPA) index for small cell lung cancer (SCLC) patients (pts) with brain metastases (BM). (2014) (0)
Abstract 1184: The effect of dual VEGF/VEGFR inhibition on angiogenic signaling pathways. (2013) (0)
1402 CANCER STEM CELL MARKER EXPRESSION IN MUSCLE-INVASIVE UROTHELIAL CARCINOMA (2011) (0)
8:08 am Functional Outcomes Following Chemoradiotherapy for Head and Neck Cancer (2003) (0)
Using novel protein antibodies on tissue microarrays (TMAs) for breast cancer prognostication (2004) (0)
EPID-14OUTCOMES IN ELDERLY PATIENTS WITH HIGH GRADE GLIOMAS (2015) (0)
Platelet Function Testing Is Commonly Performed in Patients with Known Confounding Factors (2015) (0)
310 RISK OF BONE MARROW FAILURE CONDITIONS IN PATIENTS UNDERGOING INVASIVE CARDIAC PROCEDURES (2015) (0)
Abstract P6-16-05: New graded prognostic assessment (GPA) in breast cancer brain metastases in a contemporary cohort (2015) (0)
EPID-14. OUTCOMES IN ELDERLY PATIENTS WITH HIGH GRADE GLIOMAS (2015) (0)
Alterations in T-Cell Signaling Pathways and Increased Sensitivity to Apoptosis (2004) (0)
Brain metastases: A new Graded Prognostic Assessment (GPA) index (2013) (0)
T cell infiltration in matched renal biopsy (bx) and nephrectomy (nx) samples in renal cell carcinoma (RCC). (2017) (0)
Serial serum β2 microglobulin (02m) levels correlate with multiple myeloma (mm) disease status (2000) (0)
Prognostic nomogram in elderly patients with glioblastoma. (2012) (0)
Preoperative neutrophil lymphocyte ratio as a predictor of outcomes in patients with early stage non-small cell lung cancer. (2016) (0)
Real World Outcomes of Less Well-Characterized Acute Leukemias: A Population-Based Survival Analysis Using SEER Registry (1973-2012) (2015) (0)
Evaluation of prognostic factors in upper tract urothelial carcinoma (UTUC). (2016) (0)
A Pilot Application of SELDI-TOF Mass Spectrometry in Bone Marrow Failure Syndromes. (2005) (0)
Targeting mTOR and VEGF in CRPC: Preliminary results of a phase I/II trial of temsirolimus (T) and bevacizumab (B) in docetaxel-refractory metastatic CRPC. (2012) (0)
Invited commentary (2001) (0)
Immune cell repertoire in patients with indolent metastatic renal cell carcinoma. (2013) (0)
Poster ViewingMolecular Profiling of Small Cell Bladder Cancer Reveals Gene Expression Determinants of an Aggressive Phenotype (2017) (0)
Comparative activity and toxicity of CIS-diammine dichloro platinum (DDP) adriamycin (ADR), and DDP (CAD) in disseminated transitional cell carcinomas (1981) (0)
A case-control comparison of risk factors in African-American and Caucasian women presenting with newly diagnosed breast cancer (2001) (0)
High dose therapy (HDT) and autologous stem cell transplantation (ASCT) in diffuse large B cell lymphoma (DLBL) patients with secondary central nervous system (CNS) involvement. (2004) (0)
Phase II trial of sunitinib as maintenance therapy after stereotactic radiosurgery in patients with one to three newly diagnosed brain metastases. (2010) (0)
Effects of interleukin-12 on interferon-gamma production by peripheral blood and tumor infiltrating T-lymphocytes from renal cell carcinoma patients: Evidence of impaired secretion (1996) (0)
Phase I trial of continuous Taxotere, Adriamycin, and cyclophosphamide with G-CSF (conTAC) (2001) (0)
Benefit of perioperative systemic therapy in patients with colorectal liver metastases (CRLM) undergoing liver-directed therapy (LDT). (2015) (0)
4012 POSTER Stereotactic Radiosurgery of Brain Metastases in Elderly Patients: the Cleveland Clinic Experience (2011) (0)
VHL gene mutation and hypermethylation in patients with renal cell carcinoma: Preliminary results and clinical correlation (2005) (0)
Treatment (trmt) outcome in lung transplant (LTx) recipients who develop lung cancer (LC): A Cleveland Clinic (CC) experience. (2014) (0)
Delay in time to surgery and survival in patients with type I vs type II endometrial cancer: A National Cancer Data Base analysis (2017) (0)
Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery (SRS) in patients with 1-3 newly diagnosed brain metastases. (2012) (0)
Epsilon Aminocaproic Acid (EACA) Reduces Transfusion Requirements in Patients with Thrombocytopenic Hemorrhage. (2004) (0)
MAL Is Expressed in a Subset of Hodgkin Lymphomas and Identifies a Population of Patients with Poor Prognosis. (2004) (0)
Expression of chemokine (C-C motif) ligand-2 (CCL2) is predictive of response to chemotherapy and overall survival in primary ovarian cancer (2007) (0)
Association of tumor burden characteristics with outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. (2009) (0)
294 EFFECT OF PAZOPANIB ON MYELOID DERIVED SUPPRESSOR CELLS AND T CELL FUNCTION IN METASTATIC RENAL CELL CARCINOMA PATIENTS (2013) (0)
Influence of type of antecedent disorder on outcome of therapy-related AML. (2011) (0)
Clinical predictors of prolonged clinical benefit (PCB) from pemetrexed (P) therapy in metastatic non-small cell lung cancer (mNSCLC). (2011) (0)
BMET-17. THE PROGNOSTIC ROLE OF TUMOR VOLUME IN THE OUTCOME OF PATIENTS WITH SINGLE BRAIN METASTASIS AFTER STEREOTACTIC RADIOSURGERY (2016) (0)
A Prognostic Scoring System for Newly Diagnosed Adult Acute Lymphocytic Leukemia Patients (2014) (0)
The Concept of Phenotypic Deviation: A Multiparameter Approach for Biologic Prognostic Markers in FL (2010) (0)
Post-axitinib systemic therapy in metastatic renal cell carcinoma (mRCC). (2012) (0)
Absolute neutrophil count (ANC) pattern with accelerated dose-intensified epirubicin chemotherapy and pegfilgrastim support. (2004) (0)
Prognostic value of CD56, ASCL1, and other biomarkers in small cell bladder cancer (SCBC). (2018) (0)
Newly Acquired Molecular Mutations and SNP-A Lesions Alters the Natural History of Trisomy 8 Myeloid Neoplasms (2012) (0)
CCL2 expression in ovarian carcinoma is associated with chemotherapy response and survival but not with the -2518 A/A polymorphism (2008) (0)
Final report of an open-label phase II trial of bevacizumab plus docetaxel and gemcitabine in metastatic, previously untreated nonsquamous non-small cell lung cancer (NSCLC). (2012) (0)
Impact on Pulmonary Function of Pre-Transplant Radiotherapy in Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplant (ASCT). (2008) (0)
' s report Title : Metastatic renal cell cancer treatments : An indirect comparison meta-analysis Version : 2 Date : 3 November 2008 (0)
Using novel protein antibodies on tissue microarrays (TMAs) for breast cancer prognostication. (2004) (0)
A retrospective study comparing demographics, cytogentic findings, and prognosis in acute myeloid leukemia with and without leukemia cutis (2005) (0)
A Prospective, Randomized, Chemoprevention Trial of Celecoxib for High Risk Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma (2012) (0)
Does the sequence of stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) affect treatment related morbidity in melanoma patients with brain metastasis? (2004) (0)
Suboptimal Antiplatelet Therapy Suggested By Platelet Aggregation Studies Does Not Correlate with a Change in Clinical Management (2015) (0)
Increased Tumor Infiltrating FOXP3+ Regulatory T-Cells Are Associated with Improved Survival in Classical Hodgkin Lymphoma. (2006) (0)
Myeloid derived suppressor cells (MDSC) and inflammatory biomarkers in metastatic urothelial carcinoma (mUC). (2017) (0)
The association of D4, 3-keto-abi (D4A) and response to abiraterone in castration-resistant prostate cancer (CRPC). (2016) (0)
The association of toxicities and outcomes with circulating endothelial cells (CEC) in non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (Bev). (2013) (0)
Myeloid derived suppressor cells (MDSC) correlate with inflammatory biomarkers in metastatic urothelial carcinoma (mUC) (2017) (0)
Phase I expansion study of sunitinib and bevacizumab in patients with advanced solid malignancies. (2013) (0)
Immune cell repertoire in patients with metastatic renal cell carcinoma: Data from prospective clinical trial. (2015) (0)
Outcomes of Patients with Acoustic Neuromas Treated with Gamma Knife Radiosurgery (2008) (0)
Impact of 1p Status and Radiation Therapy Timing on Long-term Outcomes for Adults With Grade 2 Glioma Treated at a Single Institution (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Paul J. Elson?

Paul J. Elson is affiliated with the following schools:

Albert Einstein College of Medicine
Medical University of South Carolina
Ewha Womans University

Paul J. Elson's Academic­Influence.com Rankings

Paul J. Elson's Degrees

Why Is Paul J. Elson Influential?

Paul J. Elson's Published Works

Published Works

What Schools Are Affiliated With Paul J. Elson?

Paul J. Elson's AcademicInfluence.com Rankings